Debulking With Excimer Laser Coronary Angioplasty Versus Balloon Angioplasty in Patients With in Stent Restenosis (ELDISR Study): A Randomized Controlled Trial

血管成形术 医学 再狭窄 累积发病率 外科 病变 气球 支架 随机对照试验 临床终点 靶病变 内科学 心肌梗塞 经皮冠状动脉介入治疗 移植
作者
Pan He,Haiwei Chen,Junjie Yang,Lei Gao,Jun Guo,Yundai Chen,Qi Wang
出处
期刊:Lasers in Surgery and Medicine [Wiley]
卷期号:57 (4): 329-338 被引量:1
标识
DOI:10.1002/lsm.70013
摘要

OBJECTIVES: Excimer laser coronary angioplasty (ELCA) is a safe and effective method for lesion preparation. However, its impact on clinical outcomes in patients with in-stent restenosis (ISR) undergoing drug-coated balloon (DCB) angioplasty remains unclear. This study aims to evaluate the effect of ELCA-based lesion preparation on the clinical outcomes of ISR patients treated with standard DCB angioplasty. METHODS: In this prospective, single-center, randomized controlled trial, patients with ISR were randomized 1:1 to either ELCA (+) or ELCA (-). The ELCA (+) group received ELCA for lesion preparation followed by standard DCB angioplasty, while the ELCA (-) group received standard DCB angioplasty alone. The primary endpoint was the rate of target lesion revascularization (TLR) within 1 year. Safety was also evaluated. RESULTS: A total of 110 patients were randomized to either the ELCA (+) group (n = 55) or the ELCA (-) group (n = 55). The mean age of the study participants was 64.5 years, 89 (80.9%) were men and 51 (46.4%) had diabetes mellitus. The procedure was successful in all patients. The primary endpoint event occurred in five patients (cumulative incidence, 9.1%) in the ELCA (+) group and in 13 patients (cumulative incidence, 23.6%) in the ELCA (-) group (HR, 0.38; 95% CI, 0.15-0.95; p = 0.038). CONCLUSIONS: Lesion preparation with ELCA before DCB angioplasty is a safe and effective strategy for patients with ISR, associated with a lower incidence of TLR compared to standard DCB angioplasty alone. However, due to the limited sample size and single-center design, these findings should be considered hypothesis-generating. Future validation requires confirmation through multicenter studies with larger patient populations. TRIAL REGISTRATION: Unique identifier: ChiCTR2300068962.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
水知寒完成签到,获得积分0
1秒前
lalala_ola完成签到,获得积分10
1秒前
杰克开膛手完成签到,获得积分10
2秒前
77发布了新的文献求助10
3秒前
ASCC完成签到 ,获得积分10
3秒前
东风完成签到,获得积分10
4秒前
5秒前
3927456843完成签到,获得积分0
5秒前
6秒前
清脆的谷波完成签到 ,获得积分10
6秒前
辣条机会有限完成签到 ,获得积分10
6秒前
彭于晏应助晶莹黎采纳,获得10
6秒前
jinyu完成签到,获得积分10
7秒前
7秒前
大力向南完成签到,获得积分10
9秒前
文文完成签到,获得积分10
9秒前
LL发布了新的文献求助10
9秒前
BioRick发布了新的文献求助10
10秒前
骑猪看月完成签到,获得积分10
10秒前
慢慢完成签到 ,获得积分10
11秒前
源来是洲董完成签到,获得积分10
11秒前
Water17完成签到,获得积分10
11秒前
嘻嘻哈哈应助白华苍松采纳,获得10
12秒前
星辰大海应助darknight采纳,获得10
12秒前
笑笑完成签到 ,获得积分10
13秒前
Lucky完成签到 ,获得积分10
13秒前
欣喜柚子完成签到 ,获得积分10
13秒前
FAN完成签到,获得积分10
13秒前
14秒前
Ming发布了新的文献求助10
15秒前
细心帽子完成签到,获得积分10
16秒前
Hello应助bai采纳,获得10
17秒前
Flora完成签到,获得积分10
18秒前
19秒前
Samuel应助科研通管家采纳,获得20
20秒前
领导范儿应助科研通管家采纳,获得10
20秒前
星辰大海应助科研通管家采纳,获得10
20秒前
梅狸猫不读博完成签到 ,获得积分10
20秒前
20秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场现状调查及投资机会研判报告 1000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场规模及竞争格局分析报告 1000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Introducing the Learning Sciences 600
Resiliency Scale for Adolescents--Chinese Version 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7324114
求助须知:如何正确求助?哪些是违规求助? 8939544
关于积分的说明 18952745
捐赠科研通 6980933
什么是DOI,文献DOI怎么找? 3215319
关于科研通互助平台的介绍 2382740
邀请新用户注册赠送积分活动 2194620